Tumour hypoxia is associated with over 70% of solid tumours including prostate and colorectal cancer. Hypoxia promotes tumour progression and resistance to treatment. Carbonic anhydrase IX (CA IX) is an endogenous marker of hypoxia. It is expressed in lung and renal cell carcinomas and is associated with a poor prognosis. CA IX has an important role in maintaining pH levels in the highly metabolically active cancer cell. The expression of CA IX in prostate cancer has not previously been investigated. Immunohistochemistry was used to examine CA IX expression in 59 patients, using tissue microarrays (TMAs) and full sections of BPH, surrounding stroma and prostate adenocarcinoma. Cores reviewed included 189 BPH, 130 Gleason grade 3, 93 Gleason grade 4, 40 Gleason grade 5. CA IX expression in colorectal cancer and HIF 1a in prostate cancer acted as positive controls. There was only occasional cell staining for CA IX expression. Although prostate cancer is a hypoxic tumour it does not express CA IX. This implies it relies on alternative pathways for maintaining pH balance in cancer. These studies would indicate that CA IX is not a suitable marker of hypoxia in prostate cancer.
Introduction
Prostate cancer is the most common solid tumour affecting men. Tumour hypoxia is characteristic of a wide range of solid tumours such as prostate, breast and head and neck tumours. 1, 2 Hypoxia promotes tumour progression 3 and resistance to therapeutic treatment 4 through reduced apoptosis, increased proliferation and angiogenesis. Tumour hypoxia can be measured by immunohistochemical analysis of endogenous markers, exogenous drugs (2-nitroimidazoles), needle probe estimation and imaging techniques. Endogenous markers commonly used in prostate cancer are HIF 1a and VEGF. 5 There are methodological difficulties as a result of extended fixation and surgical ischaemia on levels of HIF1a in addition to the dilemma of measuring nuclear or cytoplasm levels. Carbonic anhydrase IX (CA IX) has been used as an endogenous marker of hypoxia in a range of solid tumours including bladder, renal cell, lung and tumours of the head and neck. [6] [7] [8] [9] CA IX expression is associated with a more aggressive phenotype and resistance to treatment.
Hypoxia occurs in the prostate as a result of inflammation, cell remodeling, proliferating tumour cells and abnormal tumour vasculature. As a result of hypoxia cell metabolism switches to anaerobic glycolysis leading to the production of acidic metabolites. Adaptation of cells to hypoxia and acidosis is vital for cell survival and tumourigenesis. The pH of solid tumours is significantly more acidic than that of normal tissues and impairs the uptake of weakly basic chemotherapeutic drugs thus reducing their anti cancer effect on the tumours. [10] [11] [12] Carbonic anhydrases are a group of zinc-containing metalloenzymes that are involved in pH balance and the reversible conversion of carbon dioxide to bicarbonate and protons. 13 They facilitate diffusion and active transport with membrane-associated ion transport systems such as sodium hydrogen and chloride bicarbonate anion exchanger. The CAs are located in the normal mucosa of the intestinal tract, gallbladder and seminal ducts. CA IX is found in high concentrations in the rapidly dividing Krypts of Luberkuhn.
14 CA IX is upregulated in hypoxia in response to HIF 1-a binding to the hypoxia responsive element of CA IX promoter. 13, [15] [16] [17] They have a prosurvival function maintaining intra-cellular pH high preventing cell death and extracellular pH low (6.9-7.0) 18 ensuring cell growth and invasion through activation of proteolytic and signal transduction pathways. Research in CA IX has led to the development of specific inhibitors. 19 The objective of this study was to investigate if CA IX is upregulated in prostate cancer.
Materials and methods

Patients
This study included 59 patients with a wide range of Gleason scores (5-10) who underwent radical retropubic prostatectomy in the Mater Misericordiae University Hospital and St James's Hospital between 2002 and 2008 for prostate adenocarcinoma. These samples were collected as part of the Prostate Cancer Research Consortium with ethical approval.
Pathological specimens
Tissue microarrays (TMAs) and full sections were examined for CA IX expression. TMAs were constructed from 59 radical retropubic prostatectomy specimens using the Beecher Instruments Tissue-Arrayer (Beecher Instruments, Silver Spring, MD, USA). Suitable formalin-fixed paraffin-embedded blocks of each case representing as many Gleason grades as possible were selected. The corresponding Haematoxylin and Eosin-stained sections were reviewed by a pathologist (EK). One to three cores from histologically benign glands and from each grade of prostate cancer were sampled from each case where available. A total of 189 areas of histologically benign glands, 130 areas of Gleason grade 3, 93 areas of Gleason grade 4 and 40 areas of Gleason grade 5 were present on the TMAs. Representative full sections from five cases used in the TMAs were also examined for CA IX. These full sections consisted of histologically benign glands and prostate adenocarcinoma.
Immunohistochemistry
Tissue microarray sections (4 mm) and full sections underwent deparaffinization, antigen retrieval and immunohistochemistry on an automated immunohistochemistry platform (Bond Max-Leica Microsystems). 3 0 3 Daiminobenzidine was used as a chromagen with a polymer detection system, resulting in a brown end colour. Table 1 shows the optimal antigen retrieval and optimal concentrations of primary antibodies determined for immunohistochemistry. Sections were counterstained with haematoxylin. The immunohistochemical reactivity of the proteins analysed were scored in a blinded fashion with regard to histological diagnosis by a single observer (GOH), and 10% were randomly spot checked by a pathologist (EK).
Results
Immunohistochemical analysis of CA IX expression on TMAs
Overall histologically benign glands and all grades of prostate cancer had negative immunoexpression for CA IX. However, positivity was noted in the nuclei of two epithelial cells in a Gleason grade 3 tumour from one case (Figure 1k, see arrows) .
Immunohistochemical analysis of CA IX expression on full sections
There was no CA IX expression in the prostate full sections analysed. The findings of the full sections reflected those of the TMAs Discussion CA IX usually stains heterogeneously with the highest intensity adjacent to areas of necrosis or on luminal surfaces or papillary structures. 20 Renal cell carcinoma is an exception; it shows a uniform staining pattern. This is thought to be as a result of constitutively upregulated HIF 1a pathway secondary to the inactivity of the von Hippel Lindau (VHL) gene. 13 CA IX is now the best and most powerful diagnostic and predictive marker of clear cell renal cell carcinoma. 21 Renal cell carcinoma stain positively for CA IX in 94% of cases 22 and this is associated with poor prognosis. 8 In colon cancer CA IX tends to stain the epithelial cell membrane. One large study showed that it tends to stain early Dukes' stage and lymph node negative rectal cancer. 23 In transitional cell carcinoma of the bladder CA IX expression is also predominantly membranous and occurs in luminal, peri-necrotic areas or infrequently nuclear staining has been demonstrated. 6 Prostate cancer is associated with hypoxia as shown on needle electrode studies 24 and upregulation of endogenous markers of hypoxia, HIF 1-a and VEGF. 25 However, we have shown only scattered cells staining for CA IX. To ensure that hypoxic areas were not missed on TMA we also stained full sections and the results reflected that of the TMAs.
Cells use different mechanisms for pH regulation, in addition to the carbonic anhydrases there are the proton extruders; Na þ /H þ exchanger, HCO 3 À -based H þ -transporting mechanisms, monocarboxylate transporters (MCT1 & MCT4) and Vacuolar-type H þ ATPases (V-ATPases).
The V-ATPases are proton pumps composed of 14 subunits. They are organized into two domains (V 1 and V 0 ). The V 1 domain carries out hydrolysis of ATP, whereas V 0 domain carries out proton transport. They are involved in pH regulation, renal tubule acidification and bone resorption. 26 They are regulated by several mechanisms including glucose-dependent V 1 and V 0 dissociation and by their cellular localization. 27 They have been demonstrated on the apical surface of human prostate epithelial cells. 28 They are upregulated in certain 
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Monocarboxylate transporters are involved in the efflux of lactic acid, pyruvate, acetate and butyrate from the cell. 29 This is carried out through the co-transport of H þ with the above monocarboxylate anions. 30 There are four known members (MCT1-4). MCT 4 is the most common in cells with a high glycolytic rate such as tumour cells 31 and is shown to accumulate on the migrating surface of cells. 29 It is known to be inducible by hypoxia in bladder cancer cells. 32 They may have a role in the acidification of the pHe in prostate cancer. Although further studies are required to elucidate the exact pH regulation mechanism involved in prostate cancer we have given new insight into prostate cancer cell physiology and clearly demonstrated that CA IX is not expressed in cancer of the prostate.
Although prostate cancer is a hypoxic tumour it does not express CA IX and cannot be used as an endogenous marker of hypoxia. We hypothesize that the prostate depends on alternative mechanisms for pH regulation.
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